Eicosanoids and the endogenous control of acute inflammatory resolution

International Journal of Biochemistry and Cell Biology

Volumn 42, Issue 4, 2010, Pages 524-528

  Gilroy, Derek W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Inflammation; Nitric oxide; NSAIDs; Resolution

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 15 HYDROXYICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONIC ACID DERIVATIVE; CYCLOOXYGENASE 2; CYCLOPENTENONE; DELTA12 PROSTAGLANDIN J2; DOCOSAHEXAENOIC ACID; FORMYLPEPTIDE RECEPTOR LIKE 1; ICOSANOID; ICOSAPENTAENOIC ACID; ICOSATRIENOIC ACID; INDOMETACIN; LEUKOTRIENE DERIVATIVE; LIPOXIN; MARESIN DERIVATIVE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIROXICAM; PROSTAGLANDIN D2; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN J2; RESOLVIN DERIVATIVE; SALICYLIC ACID; THROMBOXANE A2; THROMBOXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CEREBROVASCULAR ACCIDENT; CHEMICAL ANALYSIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; DRUG MEGADOSE; HEART INFARCTION; HEART PROTECTION; HUMAN; IMMUNOREGULATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; LOW DRUG DOSE; NONHUMAN; PERITONITIS; PLEURISY; PROTEIN SYNTHESIS INHIBITION; REVIEW; THROMBOCYTE AGGREGATION INHIBITION;

ACUTE DISEASE; ANIMALS; ASPIRIN; EICOSANOIDS; FEEDBACK, PHYSIOLOGICAL; HUMANS; IMMUNITY, INNATE; INFLAMMATION; NITRIC OXIDE;

EID: 77649185235     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2009.12.013     Document Type: Review

References (62)

1. Anon. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
2. Ando M., Murakami Y., Kojima F., Endo H., Kitasato H., Hashimoto A., et al. Retrovirally introduced prostaglandin D2 synthase suppresses lung injury induced by bleomycin. Am J Respir Cell Mol Biol 28 (2003) 582-591
3. Ariel A., Fredman G., Sun Y.P., Kantarci A., Van Dyke T.E., Luster A.D., et al. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol 7 (2006) 1209-1216
4. Brezinski D.A., Nesto R.W., and Serhan C.N. Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 86 (1992) 56-63
5. Bystrom J., Evans I., Newson J., Stables M., Toor I., van Rooijen N., et al. Resolution-phase macrophages possess a unique inflammatory and bactericidal phenotype that is controlled by cAMP. Blood (2008) 112
6. Chatterjee P.K., Patel N.S., Cuzzocrea S., Brown P.A., Stewart K.N., Mota-Filipe H., et al. The cyclopentenone prostaglandin 15-deoxy-delta(12,14)-prostaglandin J2 ameliorates ischemic acute renal failure. Cardiovasc Res 61 (2004) 630-643
7. Chiang N., Bermudez E.A., Ridker P.M., Hurwitz S., and Serhan C.N. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A 101 (2004) 15178-15183
8. Claria J., and Serhan C.N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A 92 (1995) 9475-9479
9. Claria J., Titos E., Jimenez W., Ros J., Gines P., Arroyo V., et al. Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. Gastroenterology 115 (1998) 147-156
10. Cooper D., Russell J., Chitman K.D., Williams M.C., Wolf R.E., and Granger D.N. Leukocyte dependence of platelet adhesion in postcapillary venules. Am J Physiol Heart Circ Physiol 286 (2004) H1895-H1900
11. Cuzzocrea S., Ianaro A., Wayman N.S., Mazzon E., Pisano B., Dugo L., et al. The cyclopentenone prostaglandin 15-deoxy-delta(12,14)-PGJ2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. Br J Pharmacol 138 (2003) 678-688
12. Day R.M., Harbord M., Forbes A., and Segal A.W. Cantharidin blisters: a technique for investigating leukocyte trafficking and cytokine production at sites of inflammation in humans. J Immunol Methods 257 (2001) 213-220
13. Diab A., Deng C., Smith J.D., Hussain R.Z., Phanavanh B., Lovett-Racke A.E., et al. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 168 (2002) 2508-2515
14. Flower R.J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 26 (1974) 33-67
15. Gilroy D.W., Colville-Nash P.R., McMaster S., Sawatzky D.A., Willoughby D.A., and Lawrence T. Inducible cyclooxygenase-derived 15-deoxy(delta)12-14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB J 17 (2003) 2269-2271
16. Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J., and Willoughby D.A. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5 (1999) 698-701
17. Gilroy D.W., Lawrence T., Perretti M., and Rossi A.G. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 3 (2004) 401-416
18. Gilroy D.W., Newson J., Sawmynaden P., Willoughby D.A., and Croxtall J.D. A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation. FASEB J 18 (2004) 489-498
19. Granger D.N., and Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 55 (1994) 662-675
20. Grilli M., Pizzi M., Memo M., and Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274 (1996) 1383-1385
21. Harbord M.W., Marks D.J., Forbes A., Bloom S.L., Day R.M., and Segal A.W. Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor. Aliment Pharmacol Ther 24 (2006) 651-660
22. Hennekens C.H., Sechenova O., Hollar D., and Serebruany V.L. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions. J Cardiovasc Pharmacol Ther 11 (2006) 170-176
23. Hong S., Gronert K., Devchand P.R., Moussignac R.L., and Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 278 (2003) 14677-14687
24. Hurst S.M., Wilkinson T.S., McLoughlin R.M., Jones S., Horiuchi S., Yamamoto N., et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14 (2001) 705-714
25. Jamieson T., Cook D.N., Nibbs R.J., Rot A., Nixon C., McLean P., et al. The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol 6 (2005) 403-411
26. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
27. Kawahito Y., Kondo M., Tsubouchi Y., Hashiramoto A., Bishop-Bailey D., Inoue K., et al. 15-Deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 106 (2000) 189-197
28. Kopp E., and Ghosh S. Inhibition of NF-kappaB by sodium salicylate and aspirin. Science 265 (1994) 956-959
29. Lawrence T., Willoughby D.A., and Gilroy D.W. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2 (2002) 787-795
30. Leonard M.O., Hannan K., Burne M.J., Lappin D.W., Doran P., Coleman P., et al. 15-Epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure. J Am Soc Nephrol 13 (2002) 1657-1662
31. Levy B.D., De Sanctis G.T., Devchand P.R., Kim E., Ackerman K., Schmidt B.A., et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med 8 (2002) 1018-1023
32. Matsuoka T., Hirata M., Tanaka H., Takahashi Y., Murata T., Kabashima K., et al. Prostaglandin D2 as a mediator of allergic asthma. Science 287 (2000) 2013-2017
33. McLoughlin R.M., Jenkins B.J., Grail D., Williams A.S., Fielding C.A., Parker C.R., et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 102 (2005) 9589-9594
34. Moncada S., Palmer R.M., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43 (1991) 109-142
35. Morris T., Stables M., Hobbs A., de Souza P., Colville-Nash P., Warner T., Newson J., Bellingan G., and Gilroy D.W. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 183 (2009) 2089-2096
36. Munger K.A., Montero A., Fukunaga M., Uda S., Yura T., Imai E., et al. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc Natl Acad Sci U S A 96 (1999) 13375-13380
37. Patrono C., Ciabattoni G., Pinca E., Pugliese F., Castrucci G., De Salvo A., et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 17 (1980) 317-327
38. Paul-Clark M.J., Van Cao T., Moradi-Bidhendi N., Cooper D., and Gilroy D.W. 15-Epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 200 (2004) 69-78
39. Perretti M., Chiang N., La M., Fierro I.M., Marullo S., Getting S.J., et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med 8 (2002) 1296-1302
40. Philippidis P., Mason J.C., Evans B.J., Nadra I., Taylor K.M., Haskard D.O., et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 94 (2004) 119-126
41. Pierard-Franchimont C., and Pierard G.E. Cantharidin-induced acantholysis. Am J Dermatopathol 10 (1988) 419-423
42. Rajakariar R., Hilliard M., Lawrence T., Trivedi S., Colville-Nash P., Bellingan G., et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxydelta12 14 PGJ2. Proc Natl Acad Sci U S A 104 (2007) 20979-20984
43. Rajakariar R., Lawrence T., Bystrom J., Hilliard M., Colville-Nash P., Bellingan G., et al. Novel biphasic role for lymphocytes revealed during resolving inflammation. Blood 111 (2008) 4184-4192
44. Reilly I.A., and FitzGerald G.A. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69 (1987) 180-186
45. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
46. Samuelsson B. From studies of biochemical mechanism to novel biological mediators: prostaglandin endoperoxides, thromboxanes, and leukotrienes. Nobel Lecture, 8 December 1982. Biosci Rep 3 (1983) 791-813
47. Samuelsson B., Dahlen S.E., Lindgren J.A., Rouzer C.A., and Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237 (1987) 1171-1176
48. Savill J., Gregory C., and Haslett C. Cell biology. Eat me or die. Science 302 (2003) 1516-1517
49. Schottelius A.J., Giesen C., Asadullah K., Fierro I.M., Colgan S.P., Bauman J., et al. An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J Immunol 169 (2002) 7063-7070
50. Serhan C.N. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim Biophys Acta 1212 (1994) 1-25
51. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., and Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192 (2000) 1197-1204
52. Serhan C.N., Hamberg M., and Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci U S A 81 (1984) 5335-5339
53. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196 (2002) 1025-1037
54. Serhan C.N., Yang R., Martinod K., Kasuga K., Pillai P.S., Porter T.F., et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 206 (2009) 15-23
55. Souza M.H., de Lima Jr. O.M., Zamuner S.R., Fiorucci S., and Wallace J.L. Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol Gastrointest Liver Physiol 285 (2003) G54-G61
56. Straus D.S., and Glass C.K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 21 (2001) 185-210
57. Trivedi S.G., Newson J., Rajakariar R., Jacques T.S., Hannon R., Kanaoka Y., et al. Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. Proc Natl Acad Sci U S A 103 (2006) 5179-5184
58. Urade Y., and Hayaishi O. Prostaglandin D synthase: structure and function. Vitam Horm 58 (2000) 89-120
59. Van Dyke T.E., and Serhan C.N. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res 82 (2003) 82-90
60. Vane J., and Botting R. Aspirin and other salicylates (1992), Chapman & Hall, London
61. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231 (1971) 232-235
62. Weissmuller T., Campbell E.L., Rosenberger P., Scully M., Beck P.L., Furuta G.T., et al. PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cell-expressed ecto-NTPDases. J Clin Invest 118 (2008) 3682-3692